Associations Another Big Milestone Achieved: Collaborating with UNGC for a Better Future We've officially joined the United Nations Global Compact! This isn’t just a partnership, it’s commitment to working towards a world where business drives progress with purpose.
Associations Venus Remedies Joins United Nations Global Compact Venus Remedies joins the world's largest corporate sustainability platform, United Nations Global Compact (UNGC), aligning business operations with global sustainability.
News Unlocking a New Milestone: US FDA Grants QIDP Status to VRP-034! We are proud to share a landmark achievement in our journey at Venus Remedies Limited—one that shines a global spotlight on India’s role in tackling one of the world’s most pressing healthcare challenges: antimicrobial resistance (AMR). The U.S. Food and Drug Administration (FDA) has awarded Qualified
partnership Venus Remedies x Infex to Combat Antimicrobial Resistance in India Congratulations, Venusians. We have yet again marked another day on the calendar with gold! Venus Remedies Ltd. is delighted to announce a significant partnership with UK-based anti-infective drug development company, Infex Therapeutics. The alliance aims to tackle drug-resistant Gram-negative bacterial infections via MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor. Under this
News Featured Venus Remedies partners with UK-based Infex Therapeutics to develop anti-bacterial MET-X in India Bringing a First-in-Class MBL Inhibitor to India: Venus Remedies Licenses MET-X Venus Remedies has taken a significant step in combating Antimicrobial Resistance (AMR) by securing exclusive licensing rights for MET-X, an innovative anti-bacterial drug from UK-based Infex Therapeutics. This landmark partnership will enable Venus Remedies to develop, gain regulatory approvals,
